J. Fangman

Quantitating hemodialysis: a comparison of three kinetic models.

M. Flanigan, J. Fangman, V. Lim, 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Insulin is protein-anabolic in chronic renal failure patients.

J. Crowley, K. Yarasheski, M. Flanigan, 2003, Journal of the American Society of Nephrology : JASN.

Effect of recombinant human erythropoietin on renal function in humans.

R. Degowin, M. Flanigan, J. Fangman, 1990, Kidney international.

Hemodialysis vascular access survival: upper-arm native arteriovenous fistula.

B. Dixon, J. Fangman, Lisa Novak, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

R. Degowin, P. Kirchner, D. Zavala, 1989, Annals of internal medicine.

Thermal and spectral study of some divalent metal chelates of 2,5-dihydroxy-p-benzoquinone☆

J. Fangman, R. Bottei, 1966 .

The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency.

R. Degowin, P. Kirchner, J. Richmond, 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effect of hematocrit on solute removal during high efficiency hemodialysis.

J Fangman, V S Lim, M J Flanigan, 1990, Kidney international.